Scotiabank initiated coverage of Geron with a rating of Sector Outperform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 9/9/2024 | $7.00 | Outperform | Leerink Partners |
| 4/30/2024 | $4.50 | Outperform → Neutral | Robert W. Baird |
| 4/29/2024 | $10.00 | Buy | TD Cowen |
| 3/15/2024 | $4.00 → $5.00 | Buy | Needham |
| 9/12/2023 | $4.00 | Neutral → Buy | Goldman |
| 3/28/2023 | $3.00 | Neutral | Goldman |
| 10/28/2022 | $5.00 | Outperform | Wedbush |
Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 680,220 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. The stock options were granted on October 16, 2024, at an exercise price of $4.17 per share, which is equal to the closing price of Geron common stock on the date of grant. The stock options have a 10-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of employment for the respective employees and th
Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company, today announced that it will release its third quarter 2024 financial results and business highlights before the market opens on Thursday, November 7, 2024 via press release, which will be available on the Company's website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as business highlights at 8:00 a.m. ET the same day. A live webcast of the conference call and related presentation will be available on the Company's website at www.geron.com/investors/events. An archive of the webcast will be available on the Company's website for 30 days. Participants ma
Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 500,220 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. The stock options were granted on September 18, 2024, at an exercise price of $4.52 per share, which is equal to the closing price of Geron common stock on the date of grant. The stock options have a 10-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of employment for the respective employees and
4 - GERON CORP (0000886744) (Issuer)
4 - GERON CORP (0000886744) (Issuer)
3 - GERON CORP (0000886744) (Issuer)
Scotiabank initiated coverage of Geron with a rating of Sector Outperform
Leerink Partners initiated coverage of Geron with a rating of Outperform and set a new price target of $7.00
Robert W. Baird downgraded Geron from Outperform to Neutral and set a new price target of $4.50
Shares of General Dynamics Corporation (NYSE:GD) fell sharply during Wednesday's session after the company reported worse-than-expected second-quarter EPS results. Revenue for the quarter increased 18% year-over-year to $11.976 billion, beating the consensus of $11.438 billion. EPS of $3.26 (up 20.7% YoY) missed the consensus of $3.29, according to data from Benzinga Pro. General Dynamics shares declined 5.2% to $279.26 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers NuZee, Inc. (NASDAQ:NUZE) jumped 192% to $3.01. Dermata Therapeutics, Inc. (NASDAQ:DRMA) rose 142.4% to $3.0799 after falling over 22% on Tuesday. Selina Hospitality PLC
U.S. stock futures were lower this morning, with the Nasdaq futures dipping around 200 points on Wednesday. Shares of Tesla, Inc. (NASDAQ:TSLA) fell sharply in today's pre-market trading following second-quarter results. Tesla reported second-quarter revenue of $25.5 billion, up 2% year-over-year. The revenue total beat a Street consensus estimate of $24.73 billion, according to data from Benzinga Pro. The company reported earnings per share of 52 cents in the second quarter, down 43% year-over-year. The earnings per share missed a Street consensus estimate of 62 cents per share. The company reported second-quarter deliveries of 443,956 vehicles and production of 410,831 vehicles, d
SC 13G/A - GERON CORP (0000886744) (Subject)
SC 13G/A - GERON CORP (0000886744) (Subject)
SC 13G - GERON CORP (0000886744) (Subject)
Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, announced the appointment of Jim Ziegler as Executive Vice President, Chief Commercial Officer, effective today, September 9, 2024. In this role, Mr. Ziegler will spearhead Geron's global commercial strategy and operations, lead the commercial organization and be responsible for driving growth of RYTELO™. Mr. Ziegler has more than 25 years of commercial experience in the biopharmaceutical industry, spanning leadership, strategic and operational roles in both large and smaller organizations. "Jim brings to Geron an impressive track record of operationa
For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu
Geron Corporation (NASDAQ:GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Gaurav Aggarwal, M.D., to the Company's Board of Directors. Dr. Aggarwal has been a prominent investor in the life sciences sector for more than two decades and has a history of expertise in financial and corporate strategy, as well as business development, in companies with which he has been affiliated at both an operational and board level. "Gaurav brings extensive strategic leadership to Geron, and we believe his demonstrated track record in both corporate strategy and capital formation will add tremendous value as we look forward to a potential commercial launch in 2024
Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company, today announced that it will release its third quarter 2024 financial results and business highlights before the market opens on Thursday, November 7, 2024 via press release, which will be available on the Company's website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as business highlights at 8:00 a.m. ET the same day. A live webcast of the conference call and related presentation will be available on the Company's website at www.geron.com/investors/events. An archive of the webcast will be available on the Company's website for 30 days. Participants ma
U.S. commercial launch of RYTELO™ (imetelstat) began in June 2024 for patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia who are relapsed/refractory to or ineligible for erythropoiesis-stimulating agents (ESAs), regardless of ring sideroblast (RS) status NCCN Guidelines® updated to include the use of RYTELO in both RS+ and RS- patients for second-line treatment of symptomatic anemia in patients with lower-risk MDS and for first-line treatment of patients who are ESA ineligible (serum EPO >500 mU/mL) Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today
Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company, today announced that it will release its second quarter 2024 financial results and business highlights before the market opens on Thursday, August 8, 2024 via press release, which will be available on the Company's website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as business highlights at 8:00 a.m. ET the same day. A live webcast of the conference call and related presentation will be available on the Company's website at www.geron.com/investors/events. An archive of the webcast will be available on the Company's website for 30 days. Participants m
For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu
Submission status for GERON CORP's drug RYTELO (ORIG-1) with active ingredient IMETELSTAT has changed to 'Approval' on 06/06/2024. Application Category: NDA, Application Number: 217779, Application Classification: Type 1 - New Molecular Entity
10-Q - GERON CORP (0000886744) (Filer)
8-K - GERON CORP (0000886744) (Filer)
8-K - GERON CORP (0000886744) (Filer)